Crinetics Pharmaceuticals Inc.

This study tests an experimental drug called atumelnant in 150 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. Participants will receive either atumelnant or a placebo to see if the drug can better control hormone le…

This study tests a new drug called CRN09682 in people with advanced neuroendocrine tumors and other solid tumors that have spread and are getting worse. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About 150 adults will take part…

This study tests an experimental drug called paltusotine against a placebo in 141 adults with carcinoid syndrome caused by neuroendocrine tumors. The goal is to see if paltusotine can reduce daily episodes of flushing and diarrhea, which are common symptoms. Participants will rec…

This study tests a new medicine called atumelnant in children aged 1 to 18 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone balance. The goal is to see if the drug can safely control hormone levels and reduce the need for daily steroid medica…

This study looks at the long-term safety and effectiveness of a drug called atumelnant (CRN04894) for people with classic congenital adrenal hyperplasia (CAH). About 150 adults who have already completed a previous study with this drug will continue treatment. Researchers will mo…

This study looks at how a drug called atumelnant affects and is affected by other medicines in healthy adults. Researchers will measure drug levels in the blood to understand these interactions. The goal is to gather safety and dosing information, not to treat any disease.